Zacks: Brokerages Anticipate Radius Health, Inc. (RDUS) Will Announce Earnings of -$1.28 Per Share
Analysts predict that Radius Health, Inc. (NASDAQ:RDUS) will post ($1.28) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Radius Health’s earnings, with the lowest EPS estimate coming in at ($1.55) and the highest estimate coming in at ($0.91). Radius Health posted earnings per share of ($1.07) during the same quarter last year, which indicates a negative year-over-year growth rate of 19.6%. The firm is expected to announce its next earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Radius Health will report full year earnings of ($5.28) per share for the current financial year, with EPS estimates ranging from ($5.90) to ($4.52). For the next fiscal year, analysts expect that the firm will report earnings of ($3.99) per share, with EPS estimates ranging from ($5.27) to ($3.47). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Radius Health.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the previous year, the company earned ($1.01) earnings per share.
A number of research firms have recently commented on RDUS. Goldman Sachs Group, Inc. (The) began coverage on Radius Health in a report on Friday. They issued a “neutral” rating for the company. Jefferies Group LLC reissued a “hold” rating and set a $38.00 price objective (up previously from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Maxim Group reissued a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Finally, BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $53.60.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average cost of $35.98 per share, with a total value of $2,158,800.00. Following the completion of the purchase, the insider now directly owns 5,248,799 shares of the company’s stock, valued at $188,851,788.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 150,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average cost of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the purchase, the insider now directly owns 5,113,799 shares of the company’s stock, valued at $178,829,551.03. The disclosure for this purchase can be found here. In the last quarter, insiders bought 469,100 shares of company stock worth $16,328,382. Company insiders own 15.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of RDUS. Ameritas Investment Partners Inc. bought a new stake in shares of Radius Health in the first quarter worth about $105,000. Sei Investments Co. grew its stake in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 46 shares during the last quarter. Advisor Group Inc. grew its stake in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,888 shares during the last quarter. Finally, Blair William & Co. IL bought a new stake in shares of Radius Health in the second quarter worth about $205,000.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/zacks-brokerages-anticipate-radius-health-inc-rdus-will-announce-earnings-of-1-28-per-share.html.
Shares of Radius Health (NASDAQ:RDUS) traded down 1.07% during trading on Tuesday, reaching $38.07. The company’s stock had a trading volume of 109,477 shares. The stock has a 50-day moving average of $36.49 and a 200-day moving average of $38.70. The stock’s market cap is $1.66 billion. Radius Health has a 52-week low of $31.58 and a 52-week high of $55.97.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.